Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor Clinical Trial

Official title:

Open, Two-stage, Multicenter, Monotherapy, Phase II Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors After Failure or Intolerability to Standard Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04911907
• Other study ID #: BG01-2002
• Status: Recruiting
• Phase: Phase 2
• Start date: January 22, 2021
• Est. completion date: December 30, 2024

Study information

• Verified date: January 2023
• Source: Beijing Biostar Pharmaceuticals Co., Ltd.
• Contact: RONGGUO QIU, PhD
• Phone: 01186-5631-5388
• Email: rqiu2001[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is an open, two-stage, multi-center, phase II clinical trial to evaluate the efficacy and safety of Utidelone in advanced solid tumors (excluding breast cancer, lung cancer, and colorectal cancer) that have failed standard of treatment or were unable to perform standard treatment.

This trial is divided into 2 stages, screening stage and expansion stage. In the screening stage, 10 patients were enrolled for each tumor type(including Squamous cell carcinoma of head and neck, Esophageal cancer, Stomach cancer, Pancreatic cancer, Cholangiocarcinoma, Ovarian cancer and Other solid tumors). Based on the results of the tumor type screening stage, the sponsor and the main investigator will have a discussion and have the alignment of tumor types to enter the expansion stage. The expansion stage will refine the inclusion / exclusion criteria and may adjust the treatment plan based on the tumor type and the combination drug selection. A total of 30-50 patients (including patients enrolled in the screening stage) were enrolled in each specified tumor type during the expansion stage.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: December 30, 2024
• Est. primary completion date: March 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Histologically or cytologically documented locally-advanced and/or metastatic solid malignancy (including Squamous cell carcinoma of head and neck, Esophageal cancer, Stomach cancer, Pancreatic cancer, Cholangiocarcinoma, Ovarian cancer and Other solid tumors) that is incurable, and has failed prior standard therapy or for which standard therapy is not appropriate.

2. Have measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)

3. Age 18 -70 years old

4. ECOG performance status of 0-1

5. Life expectancy= 3 months

6. Basically normal results from routine blood test within 1 week prior to enrollment

1. Absolute neutrophil count (ANC) >= 1.5 x 10^9/L

2. Hemoglobin >= 9 g/dL

3. Platelets >= 80 x 10^9/L

7. Basically normal liver and renal functions within 1 week prior to enrollment

1. total bilirubin =< 1.5 x ULN with direct bilirubin within normal range

2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (ALT and AST =< 5 x ULN is acceptable if liver metastases are present)

3. Creatinine clearance>=50 ml/min

8. Women and men of childbearing potential must agree to take effective contraceptive measures during the study and within six months after the last treatment. Female patients must have negative urinary pregnancy test within 7 days before the first treatment (postmenopausal women must have no menstruation for at least 12 months before they are considered unable to conceive)

9. Patients who give written informed consent with good compliance.

Exclusion Criteria:

1. Received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks prior to enrollment while participating in this trial, except for the following items:

1. Nitrosourea or mitomycin C is within 6 weeks before the first dosage of the study drug;

2. Oral fluorouracil and small molecule targeted drugs are 2 weeks before the first use of the study drug or 5 half-life periods of the drug (whichever is longer);

3. The traditional Chinese medicine with anti-tumor indication is within 2 weeks before the first use of the research medicine.

2. Received other unlaunched clinical research drugs or treatment within 4 weeks before the first dosage of the research drug.

3. Have undergone major organ surgery (excluding needle biopsy) or experienced significant trauma within 4 weeks prior to the first dosage of study drug, or require elective surgery during the trial period.

4. Symptomatic peripheral neuropathy CTCAE 5.0 grade evaluation = grade 2

5. With severe allergies to castor oil, or have had serious adverse reactions with anti-microtubule drugs in the past

6. Patients of pregnancy or breast feeding

7. Patients with AEs caused by any previous treatment (including systemic and local treatment) that have not yet restored to GRADE 1 (excluding hair loss)

8. Patient with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

9. Patients with active infections and currently need systemic anti-infective treatment

10. Patient with immunodeficiency, including a positive HIV antibody test.

11. Patients with history of active hepatitis B (hepatitis B virus titer> ULN), allow prophylactic antiviral treatment other than interferon; have a history of hepatitis C virus infection (hepatitis C antibody positive).

12. Patients with history of serious cardiovascular and cerebrovascular diseases.

13. Patients with mental disorders or patients with poor compliance.

14. Patients not fitted for this study determined by the investigators.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• utidelone injection
Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle

Locations

Country	Name	City	State
China	Luhe Hospital, Capital Medical University	Beijing
China	Obstetrics and Gynecology Hospital, Capital Medical University	Beijing
China	Shanghai East Hospital of Tongji University	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Beijing Biostar Pharmaceuticals Co., Ltd.	Chengdu Biostar Pharmaceuticals

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor response to utidelone treatment	Reflected by percentage of tumor size reduction or regression, assessed by imaging techniques and expressed as Objective Response Rate (ORR) ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) according to RECIST. 1.1.	12 months from first study treatment
Secondary	Clinical benefit rate (CBR)		12 months from first study treatment
Secondary	Progression free survival (PFS)	PFS is defined as the duration of time from first study treatment to disease progression or death from any cause as documented by the investigator	18 months from first study treatment
Secondary	Safety profile associated with utidelone injection	Observe and record incidence of Treatment-Emergent Adverse Events and severe adverse effects associated with utidelone injection	18 months from first study treatment